FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response	: 0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Tatsis Ourania				2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								(Ch	eck all app Direc	licable)	10% Owne		wner		
		rst) (M RMACEUTICA	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/01/2023								belov		g. & (below)	·	
INCORPORATED 50 NORTHERN AVENUE					If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street)	N M.	A 0.	2210											Lin	X Form	filed by One filed by Mo		•	
(City)	(St		Zip)																
			I - No			_				Dis	posed of								
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				Execution Date,		3. Transaction Code (Instr. 3, 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)				Benefi	ties cially I Following	Form (D) o	wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership					
							Code	v	Amount	(A (D	() or	Price	Transa	ed ction(s) 3 and 4)			(Instr. 4)		
Common Stock 02/01/2				2023	023		A		6,194(1)	A \$		\$0.0	0 5	52,284		D			
Common Stock 02/01/2				:023		A		10,262(2)	2) A \$		\$0.0	0 62,546			D				
Common Stock 02/01/2			2023		A		7,866(3)		A	\$0.0	0 70	70,412		D					
		Tal	ble II -								osed of, convertib					d			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any			saction e (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Insi 3 and 4)		ount	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

Explanation of Responses:

- 1. Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023.
- 2. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023.
- 3. Restricted stock unit award that vests in installments beginning on 02/10/2024.

Remarks:

/s/ Christiana Stevenson, Attorney-in-Fact

02/03/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.